Loading organizations...
Loading organizations...
Biopharmaceutical company developing T-cell receptor engineered therapies.
TScan Therapeutics has raised $160.0M across 2 funding rounds.
TScan Therapeutics has raised $160.0M in total across 2 funding rounds.
TScan Therapeutics has raised $160.0M in total across 2 funding rounds.
TScan Therapeutics's investors include 6 Dimensions Capital, Bessemer Venture Partners, BlackRock, Google Ventures, Longwood Fund, Novartis, Pitango HealthTech, RA Capital Management, Astellas Venture Management, dRx Capital, Novartis Institutes for Biomedical Research, Pitango Venture Capital.
TScan Therapeutics has raised $160.0M across 2 funding rounds. Most recently, it raised $100.0M Series C in January 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 25, 2021 | $100.0M Series C | 6 Dimensions Capital, Bessemer Venture Partners, BlackRock, Google Ventures, Longwood Fund, Novartis, Pitango HealthTech, RA Capital Management | |
| Jan 9, 2020 | $60.0M Series B | 6 Dimensions Capital, Astellas Venture Management, Bessemer Venture Partners, dRx Capital, Google Ventures, Longwood Fund, Novartis Institutes for Biomedical Research, Pitango Venture Capital |